Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEVACOR vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Primary hypercholesterolemia,Mixed dyslipidemia,Homozygous familial hypercholesterolemia,Prevention of coronary heart disease,Slow progression of coronary atherosclerosis
Mild to moderate pain,Fever
10-80 mg orally once daily in the evening.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
The terminal elimination half-life of lovastatin is approximately 1-2 hours for the parent drug. However, the active metabolite (lovastatin acid) has a half-life of about 1.7-2.6 hours. Despite the short half-life, the duration of HMG-Co A reductase inhibition is prolonged due to enterohepatic recirculation and tissue distribution. Once-daily dosing is effective for LDL-C reduction.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via CYP3A4 isoenzyme; significant first-pass metabolism.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Lovastatin is primarily excreted via the biliary/fecal route (approximately 80-85% of the absorbed dose) as metabolites. Renal excretion accounts for about 10% of the administered dose, mostly as metabolites; less than 5% is excreted unchanged in urine.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Lovastatin and its active metabolite are extensively bound to plasma proteins, with binding >95% for the parent drug and >92% for lovastatin acid. The primary binding protein is albumin.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
The apparent volume of distribution (Vd) for lovastatin is approximately 0.3-0.6 L/kg, indicating distribution into tissues, but predominantly into the liver (the primary site of action). High Vd reflects extensive tissue binding.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral bioavailability of lovastatin is low, approximately 5% for the parent drug due to extensive first-pass metabolism in the liver. The active metabolite (lovastatin acid) is formed via hydrolytic metabolism. Food increases absorption, so it is recommended to be taken with the evening meal.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
No dose adjustment required for GFR >30 m L/min; if GFR <30 m L/min, start at 5 mg/day and increase cautiously.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Contraindicated in active liver disease or unexplained transaminase elevations; Child-Pugh Class A/B: use with caution, no specific dose adjustment; Child-Pugh Class C: contraindicated.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
For heterozygous familial hypercholesterolemia: 10-20 mg orally once daily in the evening for ages 10-17; adjust based on response.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Start at lower end of dosing range (10 mg/day) due to increased risk of myopathy; titrate cautiously.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
No FDA black box warning.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Myopathy/rhabdomyolysis risk increased with high doses or concomitant use of CYP3A4 inhibitors,Hepatic enzyme elevations; monitor liver function tests,Avoid use in patients with active liver disease or unexplained persistent transaminase elevations,Use caution in patients with predisposing factors for renal failure
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Active liver disease,Unexplained persistent elevations of serum transaminases,Hypersensitivity to any component of the product,Pregnancy,Lactation
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Grapefruit juice inhibits CYP3A4 and increases lovastatin levels, increasing risk of myopathy/rhabdomyolysis; avoid concurrent intake. High-fat meals enhance absorption; take with evening meal to optimize efficacy.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Pregnancy Category X. Contraindicated in all trimesters due to risk of fetal skeletal muscle damage, CNS abnormalities, and cardiac defects. Case reports of limb defects, cleft palate, and fetal death.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Contraindicated. Excreted into human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants, including interference with cholesterol biosynthesis.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Not applicable; contraindicated in pregnancy. No dose adjustments recommended as drug should be discontinued prior to conception or immediately upon pregnancy detection.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
MEVACOR (lovastatin) is a prodrug that requires CYP3A4 metabolism; avoid coadministration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, erythromycin, clarithromycin, protease inhibitors, nefazodone, grapefruit juice). Titrate dose based on LDL-C response; start at 20 mg daily with evening meal. Monitor liver function tests at initiation and as clinically indicated; contraindicated in active liver disease or unexplained transaminase elevations. Increased risk of myopathy/rhabdomyolysis with concurrent fibrates (especially gemfibrozil), niacin (>1 g/day), and CYP3A4 inhibitors. Use cautiously in patients with renal impairment.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take this medication with the evening meal to enhance absorption and reduce side effects.,Avoid consuming grapefruit or grapefruit juice while taking this drug, as it can increase the risk of side effects.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Do not take over-the-counter niacin or other cholesterol-lowering medications without consulting your healthcare provider.,Inform your doctor about all other medications, including herbal supplements and over-the-counter drugs.,Adhere to a heart-healthy diet and exercise regimen as prescribed by your healthcare provider.,Adverse effects may include headache, abdominal pain, and nausea; contact your doctor if severe or persistent.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEVACOR vs ACEPHEN, answered by our medical review team.
MEVACOR is a HMG-CoA Reductase Inhibitor (Statin) that works by Competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEVACOR and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEVACOR is: 10-80 mg orally once daily in the evening.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEVACOR and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEVACOR is classified as Category C. Pregnancy Category X. Contraindicated in all trimesters due to risk of fetal skeletal muscle damage, CNS abnormalities, and cardiac defects. Case reports of limb defects, cleft pal. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.